Physician profile
Susan A Bailey
NPI 1487742425
$2,830.50
in general payments reported to CMS, 2019-2025
28 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,247 · 2020: $176 · 2021: $438 · 2022: $356 · 2023: $288 · 2024: $106 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $908.58 | 2019 | |
| Amgen INC. | $318.53 | 2020-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $289.11 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $173.22 | 2019-2022 | |
| Lilly USA, LLC | $164.82 | 2019-2025 | Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $120.51 | 2019-2025 | Capvaxive, Gardasil 9 |
| Pfizer INC. | $90.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $82.82 | 2019-2022 | |
| Abbvie INC. | $77.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $73.00 | 2020-2022 | |
| Glaxosmithkline, LLC. | $59.47 | 2021-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.90 | 2019-2022 | |
| Smith+Nephew, INC. | $52.03 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $41.02 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $40.91 | 2024-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $38.09 | 2021 | |
| Astellas Pharma US INC | $31.86 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.83 | 2023 | Xifaxan |
| Boston Scientific Corporation | $23.04 | 2019 | |
| Radius Health, INC. | $22.24 | 2020 | |
| Viiv Healthcare Company | $21.93 | 2023 | Apretude |
| Nestle Healthcare Nutrition INC. | $21.38 | 2020 | |
| Exact Sciences Corporation | $18.61 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $17.80 | 2023 | Minimed 780g |
| Rgh Enterprises LLC | $15.84 | 2024 | |
| Acell, INC. | $15.75 | 2019 | |
| Seqirus USA INC | $15.49 | 2021 | |
| Mallinckrodt Enterprises LLC | $14.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.